Taken together, heterologous intranasal vaccination offers a promising approach for inducing memory T cells, TRM, and CD103+ DCs, providing long-lasting protection against SARS-CoV-2-induced respiratory infection. Here, ITGAE is linked to respiratory tract infectious disorder.